Bladder Neoplasm

Oncology·MeSH: Urinary Bladder Neoplasms

17 drugs in development·7 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(11)

Drug	Company
cetrelimab	GH Research PLC (GHRS)
Cetrelimab	CG Oncology, Inc. (CGON)
Intismeran autogene	Merck & Co., Inc. (MRK)
mitomycin c	GH Research PLC (GHRS)
MMC	Merus N.V. (MRUS)
tar-200	GH Research PLC (GHRS)
TAR-200	CG Oncology, Inc. (CGON)
TAR-200	Merus N.V. (MRUS)
tar-210	GH Research PLC (GHRS)
TAR-210	Merus N.V. (MRUS)
Vinblastine	ASTRAZENECA PLC (AZN)

Phase 2(3)

Drug	Company
BCG	Merck & Co., Inc. (MRK)
Cetrelimab	Merus N.V. (MRUS)
TAR-200	Janux Therapeutics, Inc. (JANX)

Phase 1(2)

Drug	Company
enfortumab vedotin	ELI LILLY & Co (LLY)
loxo-435	ELI LILLY & Co (LLY)

Phase 1/Phase 2(1)

Drug	Company
erdafitinib intravesical delivery system	GH Research PLC (GHRS)

Compare drugs

cetrelimab vs Intismeran autogene cetrelimab vs mitomycin c cetrelimab vs MMC

Frequently asked questions

How many drugs are in development for Bladder Neoplasm?

BioSniper tracks 17 drugs in development for Bladder Neoplasm across 7 companies.

How many clinical trials target Bladder Neoplasm?

There are 1 clinical trial targeting Bladder Neoplasm tracked by BioSniper.

Deep-dive into Bladder Neoplasm

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Bladder Neoplasm — Drugs in Development & Clinical Trials | BioSniper